UNCY
Unicycive Therapeutics Inc.
$5.72
+$0.20(+3.62%)
69
Overall
75
Value
63
Tech
--
Quality
Market Cap
$79.48M
Volume
252.85K
52W Range
$3.71 - $11.00
Target Price
$44.14
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | $951.0K | $675.0K | -- | ||
| Total Revenue | -- | $951.0K | $675.0K | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | -- | $951.0K | $675.0K | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $9.0M | $19.0M | $21.4M | $32.1M | ||
| Research & Development | $6.1M | $12.4M | $12.9M | $20.0M | ||
| Research Expense | $6.1M | $12.4M | $12.9M | $20.0M | ||
| Selling, General & Administrative | $2.9M | $6.6M | $8.5M | $12.1M | ||
| General & Administrative Expenses | $2.9M | $6.6M | $8.5M | $12.1M | ||
| Salaries & Wages | $966.0K | $1.0M | $1.8M | $2.4M | ||
| Depreciation & Amortization | $468.0K | $428.0K | -- | -- | ||
| Depreciation & Amortization | $468.0K | $428.0K | -- | -- | ||
| Amortization | $305.0K | $154.0K | $275.0K | -- | ||
| Other Operating Expenses | $-72.0K | $-589.0K | $-152.0K | $-958.0K | ||
| OPERATING INCOME | ||||||
| Operating income | $-9.0M | $-18.1M | $-20.8M | $-32.1M | ||
| EBITDA | $-8.5M | $-17.9M | $-30.3M | $-36.6M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $628.0K | $6.0K | $82.0K | $71.0K | ||
| Intinc | -- | -- | $615.0K | $1.3M | ||
| Net Non-Operating Interest Income/Expense | $-628.0K | $-6.0K | $615.0K | $1.3M | ||
| Other Income/Expense | $-19.0K | -- | $10.3M | $5.8M | ||
| Other Special Charges | $19.0K | -- | $-10.3M | $-5.8M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-9.0M | $-18.1M | $-30.5M | $-36.7M | ||
| Pre-Tax Income | $-9.6M | $-18.1M | $-30.5M | $-36.7M | ||
| NET INCOME | ||||||
| Net Income | $-10.0M | $-18.1M | $-30.5M | $-36.7M | ||
| Net Income (Continuing Operations) | $-10.0M | $-18.1M | $-30.5M | $-36.7M | ||
| Net Income (Discontinued Operations) | $-10.0M | $-18.1M | $-30.5M | $-36.7M | ||
| Net Income (Common Stockholders) | $-9.6M | $-18.1M | $-31.4M | $-37.8M | ||
| Normalized Income | $-7.6M | -- | -- | $-36.3M | ||
| TOTALS | ||||||
| Total Expenses | $9.0M | $19.0M | $21.4M | $32.1M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $1.2M | $1.5M | $2.5M | $67.0M | ||
| Average Shares Outstanding (Diluted) | -- | $1.5M | $2.5M | $67.0M | ||
| Shares Outstanding | $1.5M | $1.5M | $17.7M | $17.7M | ||
| Basic EPS | $-8.6 | $-12 | $-12.8 | $-0.56 | ||
| Basic EPS (Continuing Operations) | $-8.6 | $-12 | $-12.8 | $-0.56 | ||
| Diluted EPS | $-8.6 | $-12 | $-12.8 | $-0.56 | ||
| Diluted EPS (Continuing Operations) | -- | $-12 | $-12.8 | $-0.56 | ||
| Dividend Per Share | -- | -- | $287.1 | -- | ||
| OTHER METRICS | ||||||
| Accrued Preferred Stock Dividends | -- | -- | $867.0K | $1.1M | ||
| Other Gand A | $2.9M | $6.6M | $8.5M | $12.1M | ||
| Otherunder Preferred Stock Dividend | -- | -- | $867.0K | $1.1M | ||
| Preferred Stock Dividends | -- | -- | $867.0K | $1.1M | ||
| Rent And Landing Fees | $14.0K | $-173.0M | $-354.0K | $-484.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | UNCY | $5.72 | +3.6% | 252.85K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Unicycive Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW